To investigate the association of office and ambulatory 24-h pulse pressure (PP) with clinical characteristics and cardiovascular risk factors in normoalbuminuric type 2 diabetic patients enrolled to the Randomised Olmesartan and Diabetes Microalbuminuria Prevention study, 4449 patients (2054 male and 2395 female; mean age 57.7 ± 8.7 years) with type 2 diabetes, normoalbuminuria and at least one additional cardiovascular risk factor were included into the analysis. After adjustment by age, there were significant correlations between office PP and presence of hypertension (r ¼ 0.24; Po0.001), presence of cardiac and vascular disorders (r ¼ 0.17; Po0.001), metabolic syndrome (r ¼ 0.10; Po0.001), duration of diabetes (r ¼ 0.09; Po0.001), fasting blood glucose (r ¼ 0.08; Po0.001), albumin/creatinine ratio (r ¼ 0.07; Po0.001), insulin treatment, glycosylated haemoglobin (HbA1c), male gender and current smoking. In the subgroup of 1234 patients with ambulatory blood pressure measurement performed, ambulatory PP adjusted for office PP correlated with fasting blood glucose (r ¼ 0.16; Po0.001), metabolic syndrome (r ¼ 0.14; Po0.001), albumin/ creatinine ratio (r ¼ 0.11; Po0.001) and indices of glycemic control (HbA1c: r ¼ 0.11; Po0.001). In this group of normoalbuminuric type 2 diabetic patients, office and ambulatory PP were associated with duration of diabetes, indices of glycemic control and cardiovascular risk factors. There was relationship between office and ambulatory PP and albuminuria even within normal albuminuria range.
Introduction
Data from the Framingham Heart Study demonstrate that pulse pressure (PP), a surrogate of arterial stiffness, is an independent predictor of cardiovascular disease in non-diabetic individuals. [1] [2] [3] [4] [5] Several studies showed an increase in arterial stiffness in type 2 diabetic patients and in normotensive subjects with a positive family history of diabetes. 6, 7 In patients with type 2 diabetes with micro-and macrovascular complications PP is higher than in those without complications. 8 It has also been reported that PP is independently associated with cardiovascular mortality in individuals with type 2 diabetes and PP is a better predictor of coronary heart disease (CHD) events than systolic blood pressure (SBP). [9] [10] [11] The results of the FinnDiane Study showed that early age-related rise in office PP was more pronounced in subjects with diabetic nephropathy, but was also evident in diabetic subjects with normal albumin excretion. 12 Recent studies indicate that ambulatory PP may provide additional information to predict progression of albuminuria in elderly diabetic subjects, above and beyond office PP. 13, 14 A large number of past and recent studies evaluated association between PP and the risk factors of cardiovascular disease in diabetic patients with different urinary albumin excretion ranging from normoalbuminuria to microalbuminuria, the latter being an early sign of nephropathy and risk factor for cardiovascular morbidity and mortality. Recent data indicate that the association of albumin urinary excretion with major cardiac events extends to urine albumin levels below the currently accepted arbitrary cut-off point for microalbuminuria. 15, 16 In contrast to microalbuminuric type 1 and type 2 diabetic patients, the factors correlating to PP are less well established in normoalbuminuric subjects.
Therefore, the ROADMAP study (Randomised Olmesartan and Diabetes Microalbuminuria Prevention) provided a unique opportunity to evaluate the factors correlating with PP across the range of normoalbuminuric values in a large cohort of type 2 diabetic patients. The ROADMAP study will answer the question whether an angiotensin receptor blocker can prevent, or delay, the onset of microalbuminuria and whether this translates into protection against cardiovascular events and renal disease. 17 The aim was to investigate the association of both, office and ambulatory 24-h PP with clinical characteristics and cardiovascular risk factors in normoalbuminuric type 2 diabetic patients.
Patients and methods
The design of the ROADMAP study (NCT00185 159 clinicaltrials.gov) has been described in detail previously 17 and the following details, relating to the baseline data, will be briefly summarized.
Study design and organization
ROADMAP is a randomized, double-blinded, placebo-controlled, parallel-group, multicentre Phase III study that is conducted in 262 collaborating centres in 19 countries. The study protocol, which complies with the principles of Good Clinical Practice and the Declaration of Helsinki, has been approved by the relevant ethics committee at each participating centre. Written informed consent was required from each patient before enrolment in the trial.
Study population
The study has recruited 4449 patients (2054 male and 2395 female; age range 18-75 years) with type 2 diabetes (fasting plasma glucose 4126 mg per 100 ml (7.0 mmol l -1 ) and glycosylated haemoglobin (HbA1c) 46.5%, or receiving treatment for diabetes); normoalbuminuria (o35 mg (women) or o25 mg (men) albumin per gram of urinary creatinine); and at least one additional cardiovascular risk factor, including a lipid disorder defined as 4200 mg per 100 ml (5.2 mmol l -1 ) cholesterol or statin treatment, high-density lipoprotein o40 mg per 100 ml, triglycerides 4150 and o400 mg per 100 ml, hypertension ( Office blood pressure measurements were performed at each visit (between 0600 and 1100 hours) as trough readings and made three times in the sitting position (with mean calculated) and once standing, using standardized oscillometric OMRON HEM-907 blood pressure monitors. Office PP was defined as SBP minus diastolic blood pressure.
In 1234 patients, ambulatory BP monitoring (24-h ABPM) was performed at baseline visit, using BOSO TM-2430 ambulatory blood pressure measurement devices. Blood pressure was recorded for a 24-h period. Day and night time periods were defined accordingly.
Randomization, blinding and interventions
During a screening visit the potential eligibility was established by morning spot urine testing. A baseline visit was performed before randomization of the patient and after a pre-randomization phase (maximum duration 4 weeks), during which normoalbuminuria was confirmed by two additional independent morning spot urine tests. The baseline values were used for the present study.
Statistical analysis
Baseline characteristics were analyzed by following descriptive statistics: for dichotomous and categorical variables absolute and relative frequencies (counts and percents) were calculated, whereby the denominator for percents is defined as the number of patients with non-missing values.
Comprehensive data summaries were performed by means of sample characteristics for all continuous variables (n; missing n; arithmetic mean; s.d.; minimum; lower quartile; median; upper quartile; maximum; and geometric mean if appropriate).
Correlations with PP at screening were calculated for continuous and ordinal variables by means of Spearman rank correlation coefficient (univariate analysis and partial correlation adjusted for age and other factors) and multivariate regression model with stepwise selection for office PP. Estimated glomerular filtration rate was calculated using the following formula: (ml min -1 per 1.73 m 2 ) ¼ 186 Â (PCr)À1.154 Â (age in years) À0.203 ( Â 0.742, if patient is female), where PCr is serum creatinine measured in mg per 100 ml. Table 1 shows the baseline characteristics of the ROADMAP study population.
Results
At baseline the mean and median office PP value was 56.8 and 55.0 mm Hg, respectively (interquartile range 48-65 mm Hg). In the group without antihypertensive treatment (n ¼ 1447) the mean and median office PP value was 54.3 and 53.0 mm Hg, respectively (interquartile range 46-62 mm Hg).
Baseline characteristics of the study sample by office PP quartile groups are shown in Table 1 . Subjects in the higher PP quartiles were older, were characterized by longer duration of diabetes, higher fasting blood glucose, HbA1c and were more often on insulin treatment. Additionally, patients in the higher office PP quartiles more frequently had cardiac and vascular disorders, hypertension, abdominal obesity and metabolic syndrome.
Furthermore, patients in the higher office PP quartiles were characterized by more pronounced frequency of antihypertensive and anti-platelet treatments and lower percentage of subjects currently smoking. The values of estimated glomerular filtration rate were lower in subjects in the higher office PP quartiles, respectively. Higher office PP quartiles were associated with higher albumin/ creatinine ratio. All these differences were still significant after adjustment by age.
In the overall studied group, after adjustment by age, a strong correlation of PP with systolic BP was noted (r ¼ 0.78; Po0.001). Furthermore, there were significant correlations between office PP and male gender (r ¼ 0.03; P ¼ 0.035), known duration of diabetes (r ¼ 0.09; Po0.001), insulin treatment (r ¼ 0.04; P ¼ 0.004), fasting blood glucose (r ¼ 0.08; Po0.001) and HbA1c (r ¼ 0.04; P ¼ 0.005). Correlations were also found between office PP and incidence of cardiac and vascular disorders To assure that blood pressure treatment was not affecting the correlation between a specific parameter and PP, a separate analysis was performed in the group of patients without antihypertensive treatment and most of the correlations found in the whole group remained significant (Supplementary Table 1) .
In a multivariate analysis stepwise selection, independent correlations between office PP, age, male gender, known duration of diabetes, insulin treatment, fasting blood glucose, HbA1c plasma level, hypertension, metabolic syndrome, estimated GFR and albumin/creatinine ratio were found (Table 2) .
In a subgroup of 1234 patients, performing 24-h ABPM measurements at baseline, there were significant correlations between ambulatory PP and age (r ¼ 0.20; Po0.001), body mass index (r ¼ 0.15; Po0,001), hypertension (r ¼ 0.16; Po0.001), antihypertensive treatment (r ¼ 0.06; r ¼ 0.024), known duration of diabetes (r ¼ 0.14; Po0.001), cardiac and vascular disorders (r ¼ 0.16; Po0.001) and albumin/ creatinine ratio (r ¼ 0.15; Po0.001) (Supplementary Table 2) .
After adjustment by ambulatory PP, all correlations between office PP and variables, except the correlation with albumin/creatinine ratio, were still significant. After adjusting by office PP, all the correlations between ambulatory PP and variables, except the correlation with age and antihypertensive treatment, were still significant. For the correlations found both for the office PP and ambulatory PP, after adjustment by ambulatory PP and office PP, respectively, higher correlation coefficients were found for office PP with age, hypertension and cardiac and vascular disorders, and higher for ambulatory PP for body mass index (Supplementary Table 2 ).
Daytime and nighttime ambulatory PP correlated significantly with the same variables as 24-h ambulatory PP. After adjusting daytime PP for nighttime PP only the correlation with fasting glucose remained significant. In contrast, after adjusting nighttime PP for daytime PP all correlations remained significant except correlations with smoking and antihypertensive treatment status, fasting plasma glucose and HbA1c plasma level.
Discussion
The baseline data of the ROADMAP study demonstrate that in a large group of normoalbuminuric patients with type 2 diabetes office PP correlated with age, known duration of diabetes and indices of glycemic control, that is, fasting plasma glucose and HbA1c. We also found that subjects in the higher PP quartiles were older, were characterized by longer duration of diabetes, higher fasting blood glucose, HbA1c and were more often on insulin treatment.
Our data is in agreement with previous reports indicating that in a large group of patients with type 2 diabetes age, male gender and duration of diabetes were positively associated with office PP. 9 The relationship between age and PP was stronger in diabetic subjects than in non-diabetic individuals. 10 This baseline assessment of the ROADMAP study showed office PP correlations with indices of glycemic control being in a good agreement with the evidences that the metabolic alterations in type 2 diabetes are associated with increased arterial stiffness. 18 The present study in normoalbuminuric patients with type 2 diabetes revealed an association between office PP and selected cardiovascular risk factors, including age (455 years), hypertension, abdominal obesity and metabolic syndrome, as well as cardiac and vascular disorders. Patients in the Pulse pressure in diabetes A Januszewicz et al higher office PP quartiles were characterized by the more pronounced frequency of antihypertensive and anti-platelet treatments and percentage of subjects currently smoking. Our study appears to confirm other reports in diabetic patients. 1, 10, 11, 19 In a large population-based study it has been shown that the cumulative influence of cardiovascular risk factors, even treated, was an independent determinant of arterial stiffness. 19 It has been also reported that PP is independently associated with cardiovascular mortality in subjects with type 2 diabetes, and office PP is a better predictor of CHD events than SBP. 1, 10, 11 It should be noted, however, that the baseline associations between office PP and cardiovascular risk factors has not been well described in patients with type 2 diabetes and most of the prospective studies investigated the relationship between PP and risk of cardiovascular disease in non-diabetic patients. 3, 20, 21 More recently it has been suggested that office PP may be directly related to albumin excretion. In nondiabetic, middle-aged adults, PP was directly related to microalbuminuria, independent of diastolic pressure and other correlates. 22 In a recent report, based on a small number of patients with type 2 diabetes, PP was related to albumin excretion. 23 The present study showed that office PP correlated with albumin excretion within the normoalbuminuric range. In this study we also found that patients in the higher office PP quartiles were characterized by the more pronounced albumin/ creatinine ratio. Our data is in agreement with the results of Tanaka et al., who reported the relationship between PP and albuminuria, even in the group of normoalbuminuric type 2 diabetic patients. 24 Recent studies suggest that ambulatory PP may provide additional prognostic information above and beyond office blood pressure. Therefore, we compared the mulivariate-adjusted association of office PP and ambulatory PP in a subgroup of 1234 normoalbuminuric patients with type 2 diabetes, in whom ABPM measurements were performed. We found that both parameters correlated with age, known duration of hypertension and selected cardiovascular risk factors. Additionally, ambulatory PP correlated with indices of glycemic control and metabolic syndrome, and that after adjusting for office PP association did persist for ambulatory PP. It should be noted that daytime and nighttime ambulatory PP correlated with the same variables as 24-h ambulatory PP. This may suggest more pronounced relationship between ambulatory PP in metabolic profile and indices of glycemic control in this group of diabetes type 2 and normoalbuminuric patients than office PP.
Recent studies indicate that ambulatory PP was a strong predictor of the progression of albuminuria in diabetic subjects and this parameter could be important in the future risk assessment in diabetic subjects. 14 The ROADMAP study demonstrated that in the 24-h ABPM subgroup of 1234 normoalbuminuric patients with type 2 diabetes, significant correlations between both office and ambulatory PP and albumin/creatinine ratio existed. However, that association did not persist for office PP after adjusting for ambulatory PP, which outperformed office PP when evaluating relationship to albumin excretion. Knudsen et al. found a cross-sectional association between ambulatory PP and albuminuria in middle-aged Danish patients with type 2 diabetes, suggesting that ambulatory PP may provide additional information to predict progression of albuminuria in diabetic subjects above and beyond office blood pressure. 13 The present study on baseline data of the ROAD-MAP population has several limitations. First, we only presented baseline data, and further prospective evaluation is needed to assess the predictive role of PP in progression of albuminuria and risk of fatal and non-fatal cardiovascular events. Second, as previously noted, this patient group composed of normoalbuminuric diabetic type 2 patients does not permit to draw conclusions with respect to diabetic glomerular lesions. Third, these data does not provide an insight into the mechanisms that are responsible for the observed associations and no other measurements of arterial stiffness were performed to further validate our findings in this population. Fourth, a potential problem in the interpretation of these results is the high rate of anti-hypertensive medication used in this group of normoalbuminuric patients with type 2 diabetes. However, in regard of the identified associations, patients on anti-hypertensive medication did not significantly differ from those remaining off blood pressure lowering medication. Fifth, it should be noted, that only a modest correlation exists between PP and known duration of diabetes, indices of glycemic control, metabolic syndrome and albuminuria. Furthermore, the effect of these parameters on the PP wide only moderate. Therefore, these correlations point more to the direction (thus, providing a potential target of treatment) rather than reflecting the magnitude of the relationship.
The strengths and uniqueness of this study include a longitudinal design that examines the relationship between PP and the primary and potentially secondary outcomes. The studied patient group is large and well characterized. Moreover, recruited patients were characterized by no recent (o26 weeks) treatment with renin angiotensin aldosterone system inhibitors, such as angiotensin receptor blockers or angiotensin-converting enzyme inhibitors. A 24-h ABPM was performed in a large, representative subgroup of patients, using a well-validated methodology.
In summary, our data provide evidence that in this group of normoalbuminuric patients with type 2 diabetes, office PP was associated with age, known duration of diabetes, indices of glycemic control and selected cardiovascular risk factors. The relationship between PP and albuminuria, even within normal range, has been shown in these type 2 diabetic patients. The presented data may suggest a more pronounced relationship between ambulatory PP than office PP, metabolic profile and indices of glycemic control, in this group of patients. It should be noted that the associations between PP and cardiovascular risk factors might imply that PP, in addition to mean arterial pressure, may be a target for therapeutic intervention in these patients, who at baseline were off medication blocking the renin angiotensin aldosterone system.
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